TABLE 3.
Model 1 | P | Model 2 | P | |
All-cause mortality | ||||
Continuous (/1-unit increase in ln[phosphorus intake (mg/d)]) | ||||
Less than ln(1400 mg/d) | 0.78 (0.51, 1.20) | 0.2 | 0.96 (0.64, 1.43) | 0.8 |
Greater than or equal to ln(1400 mg/d) | 2.43 (1.12, 5.27) | 0.03 | 2.23 (1.09, 4.55) | 0.03 |
CVD2 mortality | ||||
Continuous (/1-unit increase in ln[phosphorus intake (mg/d)]) | ||||
Less than ln(1400 mg/d) | 0.89 (0.42, 1.88) | 0.8 | 0.99 (0.46, 2.14) | 1.0 |
Greater than or equal to ln(1400 mg/d) | 1.06 (0.25, 4.46) | 0.9 | 1.02 (0.25, 4.21) | 1.0 |
Cox proportional hazards regression was used to estimate HRs of mortality by absolute phosphorus intake. Absolute phosphorus intake was log-transformed to achieve a more normal distribution and modeled continuously by using linear splines with a knot at ln(1400 mg/d) on the basis of evidence of a nonlinear relation. Model 1 was adjusted for age, sex, race, ethnicity, poverty:income ratio, and total energy intake. Model 2 was adjusted as for model 1 and for BMI, systolic blood pressure, current and former smoking, physical activity, non–HDL cholesterol, log albumin:creatinine ratio, estimated glomerular filtration rate, and low vitamin D concentration.
CVD, cardiovascular disease.